RTP Mobile Logo
Proceedings from the First Annual Oncology Nursing Retreat
Released February 2020

Proceedings from a weekend-long symposium featuring discussion of significant new data sets, promising treatment strategies and key practical management considerations in the care of patients with breast, lung, gastrointestinal, genitourinary, gynecologic, dermatologic and select hematologic cancers. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

    OVERVIEW OF ACTIVITY
    Although medical oncologists have historically been responsible for therapeutic decision-making, interprofessional collaboration is becoming increasingly important in the provision of effective oncology care. Specifically, research has shown that oncology nurses play a critical role in the successful delivery of systemic therapy. By reinforcing or expanding upon information delivered by the treating oncologists and facilitating shared-decision-making, oncology nurses represent an important facet of a successful patient experience and a key conduit for sharing knowledge and perspectives with the patient. Additionally, because of their close connection with patients at pivotal points of care, oncology nurses have the potential to greatly contribute to the psychosocial well-being of these individuals and directly affect the nature and quality of their treatment.

    These video proceedings from a weekend-long multitumor CNE symposium feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for a broad spectrum of tumor types that account for a large portion of routine practice. By providing an educational opportunity that takes into account the crucial, unique and multifaceted role of the oncology nurse, this activity will facilitate the acquisition of knowledge and skills that will ultimately make them more effective caregivers.

    PURPOSE STATEMENT

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast, lung, gastrointestinal, genitourinary, gynecologic, dermatologic and select hematologic cancers.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, dermatologic, lung and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, dermatologic, lung and select hematologic cancers in which patients under your care may be eligible to participate.
    • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer treatment and supportive care algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.
    • Recognize adverse events associated with various therapies commonly used in the treatment of hematologic cancers and solid tumors, and offer supportive management strategies to minimize or manage side effects.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with cancer to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 14 contact hours is provided by RTP during the period of February 2020 through February 2021.

    This activity is awarded 14 ANCC pharmacotherapeutic contact hours.

    ONCOLOGY NURSING CERTIFICATION CORPORATION (ONCC)/INDIVIDUAL LEARNING NEEDS ASSESSMENT (ILNA) CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications, please visit ResearchToPractice.com/NursingRetreat2019/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/NursingRetreat2019/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Paula J Anastasia, RN, MN, AOCN
    Gyn-Oncology Clinical Nurse Specialist
    UCLA Medical Center
    David Geffen School of Medicine
    Los Angeles, California

    No relevant conflicts of interest to disclose.

    Katherine Benchich, NP, MSN, RN
    Hematology Oncology
    UCHealth Cancer Care
    Anschutz Medical Campus
    University of Colorado Cancer Center
    Denver, Colorado

    No relevant conflicts of interest to disclose.

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.

    Jamie Carroll, APRN, MSN, CNP
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Matthew S Davids, MD, MMSc
    Assistant Professor of Medicine, Harvard Medical School
    Associate Director, CLL Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Adaptive Biotechnologies, Genentech, Janssen Biotech Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Genentech, Janssen Biotech Inc, MEI Pharma, Syros Pharmaceuticals Inc, Verastem Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Ascentage Pharma, Genentech, MEI Pharma, Pharmacyclics LLC, an AbbVie Company, Verastem Inc.

    Morie A Gertz, MD, MACP
    Consultant, Division of Hematology
    Roland Seidler Jr Professor, Department of Medicine
    College of Medicine
    Mayo Distinguished Clinician
    Mayo Clinic
    Rochester, Minnesota

    Consulting Agreements: Akcea Therapeutics and Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amgen Inc, Annexon Biosciences, Apellis Pharmaceuticals, Celgene Corporation, DAVA Oncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Prothena, Spectrum Pharmaceuticals Inc, Teva Oncology; Contracted Research: Amyloidosis Foundation, International Waldenstrom’s Macroglobulinemia Foundation, NCI SPORE MM SPORE 5P50 CA 186781-04; Data and Safety Monitoring Board/Committee: AbbVie Inc.

    Amy Goodrich, CRNP
    Nurse Practitioner
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    No relevant conflicts of interest to disclose.

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center
    Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Matthew Gubens, MD, MS
    Associate Professor, Thoracic Medical Oncology
    University of California, San Francisco
    San Francisco, California

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Heron Therapeutics Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    Rhonda Hewitt, MSN, RN, ANP-BC, AOCNP
    Hematology Nurse Practitioner
    Stanford Health Care
    Stanford, California

    No relevant conflicts of interest to disclose.

    Sara Hurvitz, MD
    Associate Professor of Medicine
    David Geffen School of Medicine at UCLA
    Director, Breast Cancer Clinical Research Program
    Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
    Santa Monica, California

    Grant/Support: Ambryx Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, BioMarin, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Dignitana, Genentech, GlaxoSmithKline, Lilly, MacroGenics Inc, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; Paid Travel: Lilly, Novartis, OBI Pharma Inc.

    Rami Komrokji, MD
    Senior Member, Professor of Oncologic Sciences
    Section Head, Leukemia and MDS
    Vice Chair, Malignant Hematology Department
    Moffitt Cancer Center
    Tampa, Florida

    Advisory Committee: Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Geron, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc; Speakers Bureau: Alexion Pharmaceuticals, Jazz Pharmaceuticals Inc, Novartis.

    Ann S LaCasce, MD, MMSc
    Program Director, Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Institute Physician
    Lymphoma Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics.

    Wendi S Lee, MSN, RN, NP-C
    Department of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreement: Pfizer Inc.

    Evan J Lipson, MD
    Associate Professor, Medical Oncology
    Johns Hopkins University School of Medicine
    Bloomberg-Kimmel Institute for Cancer Immunotherapy
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee: Array BioPharma Inc, Bristol-Myers Squibb Company, EMD Serono Inc, MacroGenics Inc, Merck, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme; Contracted Research: Bristol-Myers Squibb Company, Merck, Regeneron Pharmaceuticals Inc, Sanofi Genzyme.

    Jessica Mitchell, APRN, CNP, MPH
    Assistant Professor of Oncology
    Mayo College of Medicine
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Josie Montegaard, MSN, AGPCNP-BC
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: Janssen Biotech Inc.

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, ImmunoGen Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Samumed, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics, Roche Laboratories Inc.

    Eileen M O’Reilly, MD
    Winthrop Rockefeller Chair in Medical Oncology
    Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
    Gastrointestinal Oncology Service
    Associate Director
    David M Rubenstein Center for Pancreatic Cancer
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Incyte Corporation, Lilly, Novartis.

    Elizabeth O’Reilly, MSN, MPH, ANP-BC
    Nurse Practitioner, Breast Oncology
    Susan F Smith Center for Women’s Cancers
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Daniel P Petrylak, MD
    Professor of Internal Medicine (Medical Oncology) and Urology
    Yale University
    New Haven, Connecticut

    Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.

    Daniel A Pollyea, MD, MS
    Associate Professor of Medicine
    Clinical Director of Leukemia Services
    Robert H Allen Endowed Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Aurora, Colorado

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, argenx, Celgene Corporation, Celyad, Forty Seven Inc, Gilead Sciences Inc, Janssen Biotech Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Genentech, Takeda Oncology; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc, Tolero Pharmaceuticals.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics; Data and Safety Monitoring Board/Committee: Children’s Hospital Los Angeles, Eisai Inc, US Biotest Inc.

    Tiffany A Richards, PhD, ANP-BC, AOCNP
    Nurse Practitioner
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Celgene Corporation, Takeda Oncology.

    Susan K Roethke, CRNP, MSN, ANP-BC, AOCNP
    Genitourinary Medical Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: Astellas; Speakers Bureau: Astellas, Pfizer Inc.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco Medical Center
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, Lilly, MacroGenics Inc, Merck, Mylan NV, Pfizer Inc, Puma Biotechnology Inc.

    Victoria Sinibaldi, RN, MS, CS, CANP, BC
    Adult and Geriatric Nurse Practitioner
    Research Associate in Oncology and Urology
    Faculty, School of Medicine, Johns Hopkins University
    Affiliate Staff, Johns Hopkins Hospital
    Baltimore, Maryland

    No relevant conflicts of interest to disclose.

    Eytan M Stein, MD
    Assistant Attending Physician
    Director, Center for Drug Development in Leukemia
    Leukemia Service, Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Menarini Group, Novartis, PTC Therapeutics, Seattle Genetics, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Syros Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Cellectis, Epizyme; Ownership Interest: Auron Therapeutics.

    Sarah K Swanson, ANP-BC
    Rush University Medical Center
    Department of Hematology, Oncology and Cell Therapy
    Chicago, Illinois

    No relevant conflicts of interest to disclose.

    Anne S Tsao, MD
    Professor
    Director, Mesothelioma Program
    Director, Thoracic Chemo-Radiation Program
    Department of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, Huron, Lilly, Merck, Novartis, Roche Laboratories Inc, Seattle Genetics, SELLAS Life Sciences, Takeda Oncology; Contracted Research: Ariad Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Epizyme, Genentech, Lilly, Merck, Polaris Group, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board/Committee: Xcovery.

    Amanda Wagner, APRN-CNP, AOCNP
    The Arthur G James Cancer Hospital
    Martha Morehouse Medical Plaza
    GI Medical Oncology
    Columbus, Ohio

    No relevant conflicts of interest to disclose.

    Lauren Ziskind, APN, NP-C, OCN
    Chicago, Illinois

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RTP CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, and Tesaro, A GSK Company.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: February 2020
    Expiration date: February 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):